You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Responsible Drinking: Internet-based, Interactive Computer Tailored Intervention

    SBC: Pro-Change Behavior Systems Inc            Topic: NIAAA

    DESCRIPTION (provided by applicant): Excessive alcohol use is associated with a range of serious and costly health, social, and economic consequences at the individual and societal level. This program of research serves as a venue by which to produce and test an innovative, science-based, and cost-effective means to intervene in a private, convenient, and individualized way with employed adults wh ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Computerized Stage-Matched Intervention for Juvenile Offenders

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    DESCRIPTION (provided by applicant): Juvenile crime imposes enormous costs on victims, on society, and on juvenile offenders themselves. However, research assessing the efficacy of interventions for young offenders show, on average, only small effects on recidivism, substance abuse, and other behavioral outcomes. A major problem with existing interventions is that they tend to neglect individual d ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of

    SBC: EPIVAX, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of efficacy in preparation for Phase 1 clinical trials. More than 13,000 children in the U.S. are diagnos ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Novel antithrombotic agents to prevent hemodialysis vascular access failure

    SBC: EVAS THERAPEUTICS LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Currently, more than 60 % of end-stage renal diseases patients who require chronic hemodialysis are accessed through a native arteriovenous fistula (AVF) or synthetic graft (AVG). Unfortunately, primary failure rates were as high as 60 % at 6 months after AVF creation and 77% at 1 year after AVG construction. Surgical trauma, repeated needle punctures, mechani ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Adjunctive Use of Apyrase to Fibrinolytic Therapy

    SBC: APT THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Acute myocardial infarction is the leading cause of death in most industrialized nations. The estimated annual incidence in the US is 865,000 events, with ST-segment elevation myocardial infarction (STEMI, severe AMI)comprising an estimated 500,000 events per year. Fibrinolytic therapy is widely utilized to restore coronary blood flow due to its widespread ava ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Improved long-term biocompatibility of coronary stents by plasma coating process

    SBC: NANOVA INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Improved long-term biocompatibility of coronary stents by plasma coating process Abstract Drug-eluting stents (DES) have been widely used to treat patients of cardiac disease due to their better ability to control restenosis than bare metal stents (BMS). However, a serious adverse outcome of late stent thrombosis in patients treated with DES has been reported, ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Treatment of Transplant Reperfusion with CD47 antibody

    SBC: VASCULOX, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Vasculox, Inc. is developing a humanized anti-CD47 mAb for reducing ischemia-reperfusion injury (IRI) in organ transplantation. In spite of improvements in surgical technique, organ preservation and immunosuppression, IRI remains a serious limitation and is responsible for delayed graft function, initial graft failure and contribtes to poor long-term graft surv ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Thin Diamond for Time-of-Flight Detectors

    SBC: Applied Diamond, Inc.            Topic: 35b

    Detectors and radiation monitors for future high energy and nuclear physics experiments must be able to withstand radiation environments several orders of magnitude harsher than those of any current device. At present, most radiation detectors are based on silicon technology, however, the practical radiation hardness limit of silicon falls far short of requirements in future high ener ...

    SBIR Phase I 2012 Department of Energy
  9. Novel Membrane Systems for Olefin/Paraffin Separation

    SBC: COMPACT MEMBRANE SYSTEMS, INC.            Topic: 18a

    Ethylene and propylene are the primary feedstocks for the manufacture of polyethylene and polypropylene, respectively. These olefins represent a major component of the polymer manufacturing cost. Consequently, there is significant economic benefit in minimizing losses of unreacted olefin from the process. Some olefin loss is a result of the need to remove paraffin from the polymerization reactor ...

    SBIR Phase I 2012 Department of Energy
  10. Diamond Refractive Focusing Optics

    SBC: Delaware Diamond Knives, Inc            Topic: 16a

    Synchrotron-based science has had a great scientific impact and will continue to have great impact going forward. In spite of the large investment in the 3rd generation light sources, most beam lines do not preserve the sources phase profile or brightness all the way to the sample. For these high brightness light sources, errors are almost completely due to distortion in the front-end optics cau ...

    SBIR Phase I 2012 Department of Energy
US Flag An Official Website of the United States Government